Tabula Bioscience Challenges Radical Numerics' Virus Research Claims

By Rachel Kim

Radical Numerics, a California-based AI startup, announced on October 20, 2026, that its AI-designed bacteriophages were used in treating a patient with an antibiotic-resistant bacterial infection. However, Tabula Bioscience, a former partner, claims it conducted much of the underlying research.

According to Radical Numerics, the treatment was authorized by the U.S. Food and Drug Administration under a compassionate-use pathway. The company has not disclosed specifics about the patient, clinical site, or outcomes, citing confidentiality.

Tabula Bioscience's assertion of its role in the research was reported by The New York Times and Quartz. Radical Numerics CEO Eric Nguyen acknowledged a seven-month collaboration with Tabula but cited confidentiality agreements as the reason for not naming the partner in their announcement.

The dispute has led to the resignation of Harvard geneticist George Church from Radical Numerics' board. Church, who also advises Tabula, stepped down on November 5, 2026, citing the omission of Tabula's contributions in the public announcement.

Currently, the technical report by Radical Numerics remains unverified by peer review, and no scientific study has been published to support the claims of clinical efficacy. Experts have noted that the in vitro success does not guarantee clinical effectiveness.